Navigation Links
Global Angiogenesis Inhibitors and Stimulators Industry
Date:7/3/2012

NEW YORK, July 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Angiogenesis Inhibitors and Stimulators Industry

http://www.reportlinker.com/p0459142/Global-Angiogenesis-Inhibitors-and-Stimulators-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_

This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following Product Segments: Angiogenesis Inhibitors, and Angiogenesis Stimulators. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 69 companies including many key and niche players such as Abbott Laboratories, Adnexus Therapeutics, Inc., Æterna Zentaris Inc., Amgen, Inc., Angstrom Pharmaceuticals Inc., AstraZeneca Plc, Bayer HealthCare AG, Callisto Pharmaceuticals, Inc., Celgene Corporation, Celltech Group Plc., Cephalon Inc., Eisai Inc., Eli Lilly And Company, ImClone Systems Inc., EntreMed Inc., GenVec Inc., Genzyme Corp., GlaxoSmithKline plc, Merck KGaA, Novartis, OSI Pharmaceuticals, Inc., Eyetech, Inc., Pfizer Inc., Progen Industries, Regeneron Pharmaceuticals, Roche, Genentech Inc., Chugai Pharmaceutical Co. Ltd., Silence Therapeutics, and ThromboGenics Limited. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

 

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

1. Angiogenesis Inhibitors I-3

2. Angiogenesis Stimulators I-4

 

II. EXECUTIVE SUMMARY

1. MARKET OUTLOOK II-1

Angiogenesis: In the Spotlight II-1

Angiogenesis: A Preview II-1

 

2. MARKET OVERVIEW II-2

Angiogenesis Makes Inroads: A Retrospect II-2

Angiogenesis: Ushering-In a New Era II-2

Angiogenesis: Fact File II-3

Milestones in Research Achieved Over the Years II-4

Anti-Angiogenic Drugs Market - An Overview II-5

Angiogenic Inhibitors Market to Surge II-5

The Long Journey for Anti-Angiogenesis Therapies II-5

Approved Anti-Angiogenesis Drugs in the Market II-6

Select FDA-Approved Anti-Angiogenic Drugs/ Therapeutics In

Oncology By Type Monoclonal Antibody Therapies II-6

Small Molecule Tyrosine Kinase Inhibitors II-7

Inhibitors of mTOR II-8

Other Anti-Angiogenic Agents II-8

Leading Drugs in the Market II-9

Avastin Leads the Fray II-9

 

Table 1: Select Leading Drugs in the Global

Anti-Angiogenesis Market: Annual Sales in US$ Million for

Years 2008 & 2009 (includes corresponding Graph/Chart) II-9

Overview of Select Leading Drugs II-10

Avastin II-10

Survival Benefit Conferred by Avastin II-11

Mechanism of Action II-12

General Mode of Delivery II-12

Side Effects Elicited on Administering Avastin II-12

ERBITUX™ (Cetuximab) II-12

Regulatory Approvals II-13

Erbitux in Head and Neck Cancer II-13

Glivec/Gleevec (imatinib mesylate) II-14

Herceptin (Tractuzumab) II-14

Sutent (Sunitinib) II-14

Other Regulatory Approvals II-15

Sunitinib in Various Indications II-15

Sunitinib in Renal Cell Carcinoma (RCC) II-15

Sutent in Gastrointestinal Stromal Tumors (GIST) II-16

Cost Related Issues II-16

Tarceva (Erlotinib) II-16

Other Regulatory Approvals II-16

Thalomid® (Thalidomide) II-17

 

Table 2: Thalomid - Percentage Breakdown Based on Relative

Oncology Application (includes corresponding Graph/Chart) II-17

Cilengitide II-18

Imiquimod II-18

Angiogenesis Inhibitors - Pipeline Status II-19

Select Anti-Angiogenesis Drugs in Phase III Development II-19

Select Anti-Angiogenesis Drugs in Phase II Development II-20

Select Anti-Angiogenesis Drugs in Phase I Development II-21

Select Approved Indications of Anti-VEGF/VEGFR Drugs II-21

Novel Targets for Anti-Angiogenic Activity II-22

Select Approved HER Receptor-Targeting Drugs II-22

Select Approved m-TOR Inhibitors II-22

Integrins II-23

Select Integrin Targeting Drugs under Development II-23

Angiogenic Inhibitors - By Disease Application II-23

Cancer II-23

Various Types of Cancers Targeted by Angiogenesis

Inhibitors in Phase III Clinical Development II-24

Diabetic Retinopathy II-24

Female Reproductive Cycle II-24

Psoriasis II-24

Inflammatory Diseases II-25

 

Table 3: Classification of Anti-Angiogenic Compounds Based

on Most Commonly Targeted Indication (includes

corresponding Graph/Chart) II-25

Angiogenesis Inhibitors in Eye Related Diseases II-25

Age-Related Macular Degeneration II-26

Wet AMD II-26

Dry AMD II-26

Select Anti-Angiogenic Drugs Approved by FDA for Treatment

of Eye Diseases II-27

Angiogenesis Inhibitors in Dermatology II-27

Select Drugs/Therapeutics with Angiogenic Mode of Action

Approved by FDA for Dermatology II-27

 

3. MARKET TRENDS II-28

Cancer - The Key Target Indication for Research in Anti-

Angiogenesis Drugs II-28

Avastin Continues to Record Robust Growth II-28

New Markets Offer Higher Potential for Herceptin II-28

Increased Use Drives Tarceva's Growth in Developed Markets II-28

Angiogenesis Inhibitors Continue to Dominate RCC Drug Market II-29

Votrient to Lead Renal Cell Carcinoma (RCC) Drug Market II-29

Table 4: Leading Drugs in the Global Second Line Advanced

Renal Cell Carcinoma Market (2010): Percentage Breakdown by

Value Sales for Nexavar, Torisel, Afinitor, Avastin, and

Others (includes corresponding Graph/Chart) II-30

Clinical Benefits of Votrient Over Sutent II-30

US FDA Revokes Avastin Approval for Breast Cancer II-31

 

4. ANGIOGENESIS REPERTOIRE II-32

An In-depth Insight into Angiogenesis II-32

Angiogenesis: At a Glance II-32

Requisites for Angiogenesis II-32

Endogenous Regulators of Angiogenesis II-33

Angiogenic Process: Sequence of Events II-33

Angiogenesis Process in Children II-34

Angiogenesis Process in Adults II-34

The Process of Angiogenesis in Thyroid Gland II-34

 

5. ANGIOGENESIS INHIBITORS II-35

Angiogenic Inhibitors: Basic Framework II-35

Natural Inhibitors II-35

Thrombospondin II-35

Interferon II-35

Cryptic Inhibitors II-35

Other Natural Inhibitors II-35

Natural Sources for Anti-Angiogenic Action II-36

Potential Anti-Angiogenic Drugs of Natural Origin II-36

Angiogenic Inhibitors: On the Verge of Attaining Superior

Clinical Efficacy II-36

Endogenous vs Synthetic Agents II-36

Angiogenesis Inhibitors: Classification Based on Source of

Origin II-37

Anti-Angiogenic Molecules: Classification Based on Mode of Action II-37

Broad Overview of Anti-Angiogenic Therapies II-37

Pre-Requisites for Any Drug to be an Angiogenic Inhibitor II-38

Specific Therapeutic Strategies of Anti- Angiogenesis Agents II-38

Inhibiting Angiogenesis In Vivo II-39

Antiangiogenic Tumor Therapy II-39

Antivascular Therapy: Adding a New Dimension II-39

MMPs - Exhibiting Dual Role II-39

Angiogenesis Inhibitors Vs Standard Chemotherapy II-40

Comparison Between Cytostatic Antiangiogenesis and Cytotoxic

Chemotherapy II-40

Proteoglycan Mixture: Therapeutic Powerhouse II-41

Features of VascuStatin II-41

Angiogenesis Inhibition Versus Cytotoxic Therapy II-41

Relationship Between Copper and Angiogenesis II-41

Anti-Angiogenesis Action of Pencillamine II-42

Outline of Steps Involved in Drug Discovery for Angiogenesis II-42

Drug Delivery: Their Influence on Therapeutics II-42

 

6. PROMOTERS OF ANGIOGENESIS/ ANGIOGENESIS STIMULATORS II-44

Angiogenesis Stimulators II-44

Growth Factors II-44

Angiogenic Stimulators in the Market II-44

Stimulators Exhibiting Profound Influence on Angiogenesis II-44

Vascular Endothelial Growth Factor (VEGF) II-44

VEGF and Their Influence on Diabetes and Diabetic Retinopathy II-45

Fibroblast Growth Factors (FGFs) II-45

Basic Fibroblast Growth Factor (bFGF) II-45

Placental Growth Factor (PlGF) II-45

Recombinant a4 Fragment II-46

Hepatocyte Growth Factor/ Scatter Factor (HGF/SF) II-46

Angiogenin II-46

Platelet Derived Endothelial Cell Growth Factor II-46

Applications of Angiogenic Stimulators vis-a-vis Disease

Perspective II-46

Cardiac Diseases II-46

Wound Healing and Burns II-46

Critical Limb Ischaemia II-47

Status of Angiogenic Inducers II-47

Angiogenic Therapies for Tissue Repair & Regeneration II-47

Select Devices Supporting Therapeutic Angiogenesis II-47

Angiogenesis in Ischemic Heart II-48

Factors Influencing Ischemic Angiogenesis II-48

Angiogenesis and CAD II-48

Angiogenesis in Wound Healing II-49

Factors Stimulating Wound Angiogenesis II-49

Factors Impairing Wound Angiogenesis II-49

Angiogenic Therapy Vs. Conventional Therapy II-49

Types of Angiogenesis II-50

Excessive Angiogenesis II-50

Insufficient Angiogenesis II-50

Tumor Angiogenesis II-50

Sequence of Actions II-50

Angiogenesis and Tumor Progression II-50

Oncogenes vis-a-vis Potential Pro-angiogenic Activities on

Tumor Angiogenesis II-51

Role of Angiogenesis in Skin Diseases II-51

Select Drugs & Their Targeted Application II-52

Analysis of Developmental Activities Between Decades II-52

Role of Enzymes and Inflammatory Cells in Angiogenesis II-53

Angiogenic Imbalance Augments Retinal Neovascularization II-53

Oncogenes & VE -cadherin - A Facilitating Role II-53

 

7. PRODUCT APPROVALS AND LAUNCHES II-54

FDA Withdraws Approval of AstraZeneca's NDA for IRESSA (

gefitinib) Tablets II-54

Pfizer Obtains European Approval for SUTENT® to Treat

Pancreatic NET II-54

Novartis Obtains FDA Approval of New Indication for Afinitor II-54

FDA Approves Herceptin for Treating Metastatic Adenocarcinoma II-55

Roche Introduces Avastin in China II-55

Pfizer Japan Receives Clearance for Torisel in Japan II-55

GSK Obtains European Commission's Conditional Marketing

Approval for Votrient II-56

FDA Approves Tarceva® for Maintenance Treatment of NSCLC II-56

FDA Approves GlaxoSmithKline's Votrient II-56

European Commission Grants Clearance to Torisel for Mantle

Cell Lymphoma II-56

Genetech Receives FDA Approval for Avastin in Renal Cell

Carcinoma II-57

FDA Approves Bevacizumab as Second Line Treatment for

Glioblastoma II-57

Novartis Obtains FDA Approval of Afinitor for Treating Renal

Cell Cancer II-58

 

8. PRODUCT APPROVALS AND LAUNCHES - A HISTORIC PERSPECTIVE BUILDER II-59

FDA Grants Clearance for Gleevec in Treatment of

Gastrointestinal Stromal Tumor II-59

Celgene's Thalidomide Pharmion™ Receives EC Clearance for

Treating Multiple Myeloma II-59

Genentech Obtains FDA Approval for Avastin in Breast Cancer II-59

FDA Approves Nexavar for Treatment of Hepatocellular Carcinoma II-60

Wyeth Receives EC Clearance for TORISEL in Advanced Renal Cell

Carcinoma II-60

OSI and Roche Announce Approval of Tarceva® in Japan II-60

ImClone Obtains FDA Label Expansion for Erbitux®, as Third

Line Therapy in mCRC II-60

REVLIMID® Obtains Swissmedic Authorization in Switzerland II-61

REVLIMID® Receives Marketing Approval in European Union II-61

Wyeth Obtains FDA Clearance for Marketing Torisel II-61

Chugai Obtains Approval for Avastin in Japan II-62

Pfizer Obtains FDA Approval for Sunitinib in Metastatic Renal

Cell Carcinoma II-62

FDA Approves Herceptin in HER2-Overexpressing Breast Cancer

Treatment II-62

Genentech Receives FDA Approval for Bevacizumab in Non-Small

Cell Lung Cancer II-63

Amgen Obtains FDA Approval for Vectibix Treating mCRC II-63

FDA Grants Marketing Approval for Lucentis in Wet AMD II-63

Celgene Obtains FDA Clearance for Revlimid in Multiple Myeloma II-64

FDA Approves Bevacizumab for Second Line Treatment of

Metastatic Colorectal Cancer II-64

Celgene Obtains FDA's Accelerated Approval for THALOMID II-65

Celgene Obtains sNDA Approval for THALOMID from FDA II-65

ImClone Obtains FDA Clearance for Erbitux® in the treatment of

SCCHN II-65

Pfizer's Sutent Receives FDA Nod for Treatment of

Gastrointestinal Stromal Tumor II-66

Celgene Receives FDA's Subpart H Approval for Revlimid in

Myelodysplastic Syndromes II-66

US FDA Approves OSI's Tarceva® for Treating Pancreatic Carcinoma II-66

 

9. RECENT INDUSTRY ACTIVITY II-68

Valeant to Take Over Eyetech II-68

Teva Acquires Cephalo II-68

Genentech to Carry Out Additional Trial of Avastin in Her2-

negative mBC II-68

Pfizer to Seek regulatory Clearance for Axitinib in Europe and US II-68

FDA to Withdraw Avastin's Approval for Breast Cancer II-69

Eyetech Receives QTDP Grant To Develop Extended- Release

Formulation of Macugen® II-69

sanofi-aventis and Regeneron to Continue VELOUR Trial as Planned II-69

EntreMed Enters into Financing Deal for ENMD-2076 Development II-69

Chugai Pharmaceuticals Fulfills Condition for Avastin's Approval II-70

Gilead Sciences to Take Over CGI Pharma II-70

Mersana Commences XMT-1107 Phase I Clinical Trial II-70

Astellas Pharma Acquires OSI Pharmaceuticals II-71

Roche to Conduct a Trial on Anti-Cancer Antibody TB-403 II-71

Mersana Therapeutics Inks License Agreement With Teva II-71

Acceleron Publishes Pre-clinical Data Study on ACE-041 II-72

Antisense Raises Capital to Continue Phase III Trabedersen Trial II-72

GSK Receives Positive Opinions from EMEA for Two Cancer Medicines II-72

EMEA Issues Positive Opinion on GSK's Votrient II-73

EMEA Issues Positive Opinion on GSK's Anti Cancer Drug

Candidate, Tyverb II-73

Abbott Enters into Licensing Agreement with Pierre Fabre II-73

Arno Therapeutics Inks Global Licensing Agreement with OSU II-73

BI Initiates Late Stage Clinical Trials for Two Oncology Drug

Candidates II-74

AnGes Obtains US FDA Approval for Phase III Trial of Collategene™ II-74

Silence Therapeutics and Intradigm Merge II-74

Mersana Launches First Phase of XMT-1107 Clinical Trial II-75

ImClone Receives Complete Response Letter for Erbitux® sBLA

From FDA II-75

Oxigene Releases Encouraging Data from OXi4503 Pre-clinical

Studies II-76

Potentia Enters into Licensing and Purchase Option Deal with

Alcon II-76

Quark Receives Additional Patents for RTP 801 Gene Targeting

Compounds II-77

Simcere Enters into Collaboration Deal with OSI Pharmaceuticals II-77

Pfizer Acquires Wyeth in Cash & Stock Merger II-78

Gene Signal Releases Interim Results from Phase II Study on

GS-101 II-78

Onco to Conduct Second Phase Trial of Fuso's OTS102 II-78

Green Cross Obtains US FDA Approval for Greenstatin Clinical

Trial II-79

OXiGENE Acquire Symphony ViDA II-79

Roche Releases Positive Results from Phase III Trial of Lucentis II-79

Pfizer Halts Phase III Sutent Study for Colorectal Cancer II-80

Morphotek Obtains FDA Clearance for MORAb-004 IND Application II-80

GlaxoSmithKline Files MAA for Pazopanib in EU II-80

Roche Acquires Genentech II-80

Fuso Commences Phase II/III Clinical Trail for OTS102 II-81

 

10. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-82

EntreMed to Funnel Resources on ENMD-2076 Development II-82

OmegaGenesis Enters Into Collaboration with Mayo Clinic for

Angiogenesis Research II-82

Eli Lilly Acquires ImClone Systems II-82

EntreMed Demonstrates Antitumor Effects of ENMD-2076 II-83

EntreMed Collaborates with JSB for ENMD-2076 Business Development II-83

Circadian Technologies Limited Acquires Vegenics II-83

Fuso and OTS to Initiate Phase II Trial for OTS102 II-83

EntreMed Releases Pre-Clinical Findings of ENMD-2076 in

Multiple Myeloma II-83

Merck Serono Inks Development and Licensing Agreement with

Bionomics II-84

Roche Inks Licensing Agreement with ThromboGenics and

BioInvent for TB-403 II-84

Aida Initiates Pre-Clinical Development of New Anti-Cancer Drug II-85

Cyclacel Pharmaceuticals Releases Pre-Clinical Data of CYC116 II-85

Astellas and CoMentis Ink Agreement to Develop and

Commercialize Beta- Secretase Inhibitors II-86

Kringle Pharma's NK4 Receives Patent Approval in Japan II-86

UCB Releases Phase II Results of CDP791 in NSCLC Treatment II-87

Celgene Takes Over Pharmion II-87

REVLIMID® Obtains Orphan Drug Designation in Japan II-87

TRACON Commences Phase I Clinical Trial on TRC105 II-87

Ark Therapeutics to Acquire Lymphatix II-88

Access Takes Over Somanta II-88

Pfizer Takes Over CovX II-88

Callisto Restructures Licensing Agreement with Genzyme for

Atiprimod II-89

EntreMed Receives FDA Approval for ENMD-2076 IND Application II-89

EC Grants Orphan Medicinal Status to REVLIMID for Treatment of

CLC II-90

Bristol-Myers Squibb Snaps Up Adnexus Therapeutics II-90

Morvus Takes Over Two Companies II-90

Merck Inks Agreement with BMS and ImClone for Erbitux®

Development And Commercialization II-91

FDA Issues a Safety Labeling Update for Bevacizumab Drug II-91

Fuso Initiates Phase I Clinical Study for OST102 Angiogenesis

Inhibitor II-91

CRC to Support Bionomics in BN069 Development II-92

Peregrine Secures Licensing Rights for B2GP1 Angiogenesis

Inhibitor II-92

AnGes's Angiogenesis-Stimulating Drug Meets Primary End-Point

in Phase III Study II-92

ImClone Annuls Development Agreement with UCB II-92

ArQule Partners with Kyowa Hakko in Cancer Compound II-93

Samaritan Snaps Up Metastatin Pharmaceuticals II-93

EU Approves €2 Million Grants for VASOPLUS Consortium II-93

MGH Cancer Center Reports Results of AZD2171 Phase II Trial II-93

AVEO Inks Exclusive Licensing Agreement with Kirin for Novel

Anti-Cancer Compound II-94

Sangamo and Edwards Ink Angiogenesis Asset Purchase Agreement II-94

Covalon Secures Perfusion's Gene Therapy Solutions II-94

Vical Strengthens Angiogenesis and Poloxamers IPR Portfolio II-95

Biomira Takes Over ProIX Pharmaceuticals II-95

FDA Gives Out Warning on Bevacizumab Drug II-95

Athenagen Merges with Zapaq II-95

Tigris Secures Global Licensing Rights to Develop and

Commercialize New Cancer Therapies II-96

Bayer Yakuhin Files Marketing Application for Nexavar in Japan II-96

Athenagen Purchases Assets of Osprey Pharmaceutical II-96

Amgen Acquires Abgenix II-96

Genmab Enters Exclusive Licensing Agreement with Bionomics II-97

OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals II-97

FDA Changes Labeling of Iressa, Limiting Use to NSCLC II-97

Schering AG and Novartis Signs a Agreement to Commercialize

Angiogenesis Inhibitor, PTK787 II-98

Bausch & Lomb Signs an Option Agreement with PTC Therapeutics II-98

Bausch & Lomb Receives License from Cephalon, Inc II-98

Pharmacopeia Signs a Licensing Agreement with Allergan II-99

Xantos Biomedicine and Cryptome Enters into Licensing Agreement II-99

EntreMed Receives US Patent II-99

 

11. FOCUS ON SELECT GLOBAL PLAYERS II-100

Abbott Laboratories (USA) II-100

Adnexus Therapeutics, Inc. (USA) II-100

Æterna Zentaris Inc. (Canada) II-100

Amgen, Inc. (USA) II-101

Angstrom Pharmaceuticals Inc. (USA) II-101

AstraZeneca Plc. (UK) II-102

Bayer HealthCare AG (Germany) II-102

Callisto Pharmaceuticals, Inc. (USA) II-103

Celgene Corporation (USA) II-104

Celltech Group Plc. (UK) II-104

Cephalon Inc. (USA) II-104

Eisai Inc. (USA) II-105

Eli Lilly And Company (USA) II-105

ImClone Systems Inc. (USA) II-105

EntreMed Inc. (USA) II-106

GenVec Inc. (USA) II-107

Genzyme Corp. (USA) II-107

GlaxoSmithKline Plc (UK) II-107

Merck KGaA (Germany) II-108

Novartis (Switzerland) II-108

OSI Pharmaceuticals, Inc. (USA) II-109

Eyetech, Inc. (USA) II-110

Pfizer Inc. (USA) II-110

Progen Industries (Australia) II-111

Regeneron Pharmaceuticals II-111

Roche (Switzerland) II-112

Genentech Inc. (USA) II-113

Chugai Pharmaceutical Co. Ltd. (Japan) II-114

Silence Therapeutics II-115

ThromboGenics Limited (Ireland) II-115

 

12. GLOBAL MARKET PERSPECTIVE II-116

Table 5: World Recent Past, Current & Future Analysis for

Angiogenesis Inhibitors & Stimulators by Geographic

Region/Country - US, Europe and Rest of World Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2003 through 2010 (includes corresponding Graph/Chart) II-116

 

Table 6: World Historic Review for Angiogenesis Inhibitors &

Stimulators by Geographic Region/Country - US, Europe and Rest

of World Markets Independently Analyzed with Annual Sales in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) II-117

 

Table 7: World 15-Year Perspective for Angiogenesis Inhibitors

& Stimulators by Geographic Region/Country - Percentage

Breakdown of Dollar Sales for US, Europe and Rest of World

Markets for Years 2003, 2011 and 2017 (includes corresponding

Graph/Chart) II-118

 

Table 8: World Recent Past, Current & Future Analysis for

Angiogenesis Inhibitors by Geographic Region/Country - US,

Europe and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) II-119

 

Table 9: World Historic Review for Angiogenesis Inhibitors by

Geographic Region / Country - US, Europe and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-120

 

Table 10: World 15-Year Perspective for Angiogenesis

Inhibitors by Geographic Region/Country - Percentage Breakdown

of Dollar Sales for US, Europe and Rest of World Markets for

Years 2003, 2011 and 2017 (includes corresponding Graph/Chart) II-121

 

Table 11: World Recent Past, Current & Future Analysis for

Angiogenesis Stimulators by Geographic Region/Country - US,

Europe and Rest of World Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) II-122

 

Table 12: World Historic Review for Angiogenesis Stimulators

by Geographic Region / Country - US, Europe and Rest of World

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-123

 

Table 13: World 15-Year Perspective for Angiogenesis

Stimulators by Geographic Region/Country - Percentage

Breakdown of Dollar Sales for US, Europe and Rest of World

Markets for Years 2003, 2011 and 2017 (includes corresponding

Graph/Chart) II-124

 

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Angiogenic Inhibitors III-1

List of FDA Approved Anti-Angiogenic Drugs III-1

Pipeline Status By Disease III-2

Anti-Angiogenesis Therapeutics In Phase III Development

for Renal Cell Carcinoma: As of 2010 III-2

Anti-Angiogenesis Therapeutics In Phase III Development

for Breast Cancer Treatment: As of 2010 III-3

Angiogenesis Stimulators III-4

Historical Market Snapshots III-4

Market Influencers III-5

Types of Drug Approvals III-5

New Drug Approval (NDA) III-5

Orphan Drug Act III-5

Benefits Derived on Successful Grant of Orphan Drug Status III-5

Angiogenesis Foundation III-5

Key Role of the Foundation in Angiogenesis III-5

The Rising Concern III-6

Cancer III-6

Cancer Statistics in US III-6

A Picture of Colon Cancer in the US III-6

Pancreatic Cancer III-6

Vital Statistics III-7

 

Table 14: New Cancer Cases in the US By Affected Site:

2009 III-7

 

Table 15: New Cancer Cases in Males in US by Leading Site:

2009 (includes corresponding Graph/Chart) III-9

 

Table 16: New Cancer Cases in Females in US by Leading

Site:2009 (includes corresponding Graph/Chart) III-10

 

Table 17: Cancer Related Deaths in the US By Affected

Site:2009 III-11

 

Table 18: Cancer Related Deaths in Males in US by Leading

Site: 2009 (includes corresponding Graph/Chart) III-13

 

Table 19: Cancer Related Deaths in Females in US by

Leading Site: 2009 (includes corresponding Graph/Chart) III-14

AMD and DME Incidence in the US III-14

Rheumatoid Arthritis: Another Emerging Threat III-15

Diabetic Retinopathy III-15

Coronary Artery Disease (CAD) III-15

Myocardial Infarction Statistics in the US III-15

Peripheral Arterial Disease III-15

B.Market Analytics III-16

 

Table 20: The US Recent Past, Current & Future Analysis for

Angiogenesis Inhibitors & Stimulators by Product

Segments-Angiogenesis Inhibitors and Angiogenesis

Stimulators Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2009 through 2015 (includes

corresponding Graph/Chart) III-16

 

Table 21: The US Historic Review for Angiogenesis Inhibitors &

Stimulators by Product Segments- Angiogenesis Inhibitors

and Angiogenesis Stimulators Markets Independently Analyzed

with Annual Sales in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) III-17

 

Table 22: The US 15-Year Perspective for Angiogenesis

Inhibitors & Stimulators by Product Segments - Percentage

Breakdown of Dollar Sales for Angiogenesis Inhibitors &

Stimulators for Years 2003, 2011 and 2017 (includes

corresponding Graph/Chart) III-18

 

2. EUROPE III-19

A.Market Analysis III-19

Angiogenesis Market - A Historic Perspective III-19

Cancer Trends III-19

 

Table 23: Cancer Incidence in Europe by Site (2009)

(includes corresponding Graph/Chart) III-20

B.Market Analytics III-21

 

Table 24: European Recent Past, Current & Future Analysis

for Angiogenesis Inhibitors & Stimulators by Product

Segments-Angiogenesis Inhibitors and Angiogenesis

Stimulators Markets Independently Analyzed with Annual

Sales in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-21

 

Table 25: European Historic Review for Angiogenesis

Inhibitors & Stimulators by Product Segments- Angiogenesis

Inhibitors and Angiogenesis Stimulators Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding

Graph/Chart) III-22

 

Table 26: European 15-Year Perspective for Angiogenesis

Inhibitors & Stimulators by Product Segments - Percentage

Breakdown of Dollar Sales for Angiogenesis Inhibitors &

Stimulators for Years 2003, 2011 and 2017 (includes

corresponding Graph/Chart) III-23

 

3. REST OF WORLD III-24

A.Market Analysis III-24

Japanese Market III-24

Quest for New Opportunities III-24

B.Market Analytics III-25

 

Table 27: Rest of World Recent Past, Current & Future

Analysis for Angiogenesis Inhibitors & Stimulators by

Product Segments-Angiogenesis Inhibitors and Angiogenesis

Stimulators Markets Independently Analyzed with Annual Sales

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-25

 

Table 28: Rest of World Historic Review for Angiogenesis

Inhibitors & Stimulators by Product Segments- Angiogenesis

Inhibitors and Angiogenesis Stimulators Markets

Independently Analyzed with Annual Sales in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) III-26

 

Table 29: Rest of World 15-Year Perspective for Angiogenesis

Inhibitors & Stimulators by Product Segments - Percentage

Breakdown of Dollar Sales for Angiogenesis Inhibitors &

Stimulators for Years 2003, 2011 and 2017 (includes

corresponding Graph/Chart) III-27

IV. COMPETITIVE LANDSCAPE

 

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 85)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 50

Canada 2

Japan 3

Europe 22

France 2

Germany 5

The United Kingdom 6

Italy 3

Rest of Europe 6

Asia-Pacific (Excluding Japan) 8

------------------------------------------

To order this report: Drug and Medication Industry: Global Angiogenesis Inhibitors and Stimulators Industry

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
Breaking Medicine News(10 mins):